Amsterdam\/ Bonn \u2014 The Amster\u00addam-based venture capi\u00adtal fund INKEF Capi\u00adtal has sold its stake in Cardior Phar\u00admaceu\u00adtic\u00adlas to Novo Nordisk. The purchase price amounts to \u20ac1.025 billion, inclu\u00adding an upfront payment and addi\u00adtio\u00adnal payments if certain deve\u00adlo\u00adp\u00adment and commer\u00adcial mile\u00adsto\u00adnes are achie\u00adved. HTGF, one of the leading Euro\u00adpean seed inves\u00adtors, will also sell its shares as part of the tran\u00adsac\u00adtion. HTGF parti\u00adci\u00adpa\u00adted in the first finan\u00adcing round in 2017. At this early stage, HTGF belie\u00adved in the team\u2019s vision and the poten\u00adtial of RNA technology.<\/p>\n
Comple\u00adtion of the acqui\u00adsi\u00adtion is subject to the appr\u00adoval of the rele\u00advant autho\u00adri\u00adties and other custo\u00admary market condi\u00adti\u00adons and is expec\u00adted to take place in the second quar\u00adter of 2024.<\/p>\n
Cardior is a leader and pioneer in the disco\u00advery and deve\u00adlo\u00adp\u00adment of RNA-targe\u00adted thera\u00adpies for the preven\u00adtion, repair and rever\u00adsal of heart dise\u00adase. The company\u2019s thera\u00adpeu\u00adtic approach targets charac\u00adte\u00adristic non-coding nucleic acids as a plat\u00adform for addres\u00adsing the causes of cardiac dysfunc\u00adtion with the aim of achie\u00adving a lasting effect in patients.
\nNovo Nordisk is an inter\u00adna\u00adtio\u00adnal phar\u00admaceu\u00adti\u00adcal company head\u00adquar\u00adte\u00adred in Denmark that has deve\u00adlo\u00adped into one of the worl\u00add\u2019s leading insu\u00adlin manufacturers.<\/p>\n
\u201cThis acqui\u00adsi\u00adtion reflects the trans\u00adfor\u00adma\u00adtive poten\u00adtial of CDR132L as a dise\u00adase-modi\u00adfy\u00ading therapy for heart fail\u00adure,\u201d said Dr. Clau\u00addia Ulbrich, CEO and co-foun\u00adder of Cardior<\/strong>. \u201cNovo Nordisk is the ideal part\u00adner due to its exten\u00adsive clini\u00adcal and commer\u00adcial exper\u00adtise combi\u00adned with its resour\u00adces to acce\u00adle\u00adrate our late-stage deve\u00adlo\u00adp\u00adment program, inclu\u00adding through larger pivo\u00adtal trials. We look forward to advan\u00adcing CDR132L to market approval.\u201d<\/p>\n The agree\u00adment covers Cardior\u2019s lead compound CDR132L, which is curr\u00adently in Phase 2 clini\u00adcal deve\u00adlo\u00adp\u00adment for the treat\u00adment of heart fail\u00adure. \u2014 The acqui\u00adsi\u00adtion is an important step in Novo Nordis\u00adk\u2019s stra\u00adtegy to build a presence in cardio\u00advas\u00adcu\u00adlar dise\u00ada\u00adses. Novo Nordis\u00adk\u2019s goal is to build a focu\u00adsed, effec\u00adtive therapy port\u00adfo\u00adlio through inter\u00adnal and exter\u00adnal inno\u00adva\u00adtion to address the signi\u00adfi\u00adcant unmet need in cardio\u00advas\u00adcu\u00adlar dise\u00adase, the worl\u00add\u2019s leading cause of death.<\/p>\n About INKEF Capital Consul\u00adtant INKEF: YPOG<\/strong><\/p>\n Dr. Martin Scha\u00adper<\/strong> (Lead, M&A\/Transactions), Part\u00adner, Berlin Dr. Johan\u00adnes Janning (M&A\/Transactions), Part\u00adner, Cologne About YPOG<\/strong><\/p>\n YPOG is a law firm specia\u00adli\u00adzing in tax and commer\u00adcial law, active in the core areas of funds, tax, banking + finance and tran\u00adsac\u00adtions. The YPOG team advi\u00adses a wide variety of clients. These include emer\u00adging tech\u00adno\u00adlogy compa\u00adnies and family-run medium-sized enter\u00adpri\u00adses as well as corpo\u00adra\u00adti\u00adons and private equity\/venture capi\u00adtal funds. YPOG is one of the leading addres\u00adses for venture capi\u00adtal, private equity and fund struc\u00adtu\u00adring in Germany. Today, YPOG employs more than 120 expe\u00adri\u00aden\u00adced lawy\u00aders, tax consul\u00adtants, tax specia\u00adlists and a notary in three offices in Berlin, Hamburg and Colo\u00adgne. http:\/\/www.ypog.law<\/p>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":" Amsterdam\/ Bonn \u2014 The Amster\u00ad\u00addam-based venture capi\u00adtal fund INKEF Capi\u00adtal has sold its stake in Cardior Phar\u00admaceu\u00adtic\u00adlas to Novo Nordisk. The purchase price amounts to \u20ac1.025 billion, inclu\u00adding an upfront payment and addi\u00adtio\u00adnal payments if certain deve\u00adlo\u00adp\u00adment and commer\u00adcial mile\u00adsto\u00adnes are achie\u00adved. HTGF, one of the leading Euro\u00adpean seed inves\u00adtors, will also sell its shares [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":51103,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366,1367,1368,1369,1373],"tags":[],"class_list":["post-51096","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","category-lawyers-tax-advisors-auditors-en","category-lawyers-tax-consultants-auditors","category-investors","category-venture-capital-en"],"yoast_head":"\n
\n<\/strong>
\nINKEF is a leading venture capi\u00adtal firm based in Amster\u00addam that supports early-stage compa\u00adnies in Europe, Reitze Douma (photo \u00a9 INKEF) is Mana\u00adging Part\u00adner. \u2014 As a long-term inves\u00adtor, INKEF is in a posi\u00adtion to accom\u00adpany compa\u00adnies through seve\u00adral rounds of finan\u00adcing up to the IPO. INKEF supports tech\u00adno\u00adlogy and life science compa\u00adnies in deve\u00adlo\u00adping their ideas into successful inter\u00adna\u00adtio\u00adnal compa\u00adnies. The best-known invest\u00adments include GitLab, Remote, Chan\u00adne\u00adlEn\u00adgine, Silver\u00adflow, iOnc\u00adtura and Castor. www.inkef.com.<\/p>\n
\nDr. Malte Berg\u00admann (Tax), Part\u00adner, Hamburg
\nBarbara Hasse (M&A\/Transactions), Senior Asso\u00adciate, Berlin Dr. Jacob Schrei\u00adber (Tax), Senior Asso\u00adciate, Hamburg<\/p>\n